Photo from Elvina Almuradova/X
Sep 29, 2024, 16:20
Elvina Almuradova: Using ICis as a first-line treatment may pose a risk of toxicity in unresectable ESCC
Elvina Almuradova, Associate Professor of Oncology at Medicana Sağlık Grubu, shared a post on LinkedIn:
“The FDA has expressed concern that in patients with metastatic or unresectable esophageal squamous cell carcinoma, using immune checkpoint inhibitors as a first-line treatment may pose a risk of toxicity without offering a clear benefit for those with low PD-L1 expression (PD-L1 <1).”
Read further.
Source: Elvina Almuradova/LinkedIn
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 6, 2024, 12:38
Nov 6, 2024, 12:35
Nov 6, 2024, 12:35
Nov 6, 2024, 12:26
Nov 6, 2024, 12:01